DDX18

Across TCGA pan-cancer cohorts, DDX18 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DDX18 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DDX18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DDX18 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where DDX18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.317	0.778	<.001	46	view →
LSCC	DFS	Median	II,III,IV	0.857	0.532	.007	11	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LUAD	OS	Tertile	II,III,IV	0.326	0.871	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DDX18–CCRCC (DFS)

Open the CCRCC breakdown →